NLS Pharmaceutics to Present at the 35th Annual Roth Conference
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
ZURICH, SWITZERLAND / ACCESSWIRE / March 1, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced Alex Zwyer, CEO, will be presenting at the 35th Annual Roth Conference.
瑞士秀克黎世/ACCESSWIRE/2023年3月1日/瑞士臨床階段生物製藥公司NLS製藥有限公司(納斯達克代碼：NLSP，NLSPW)今天宣佈，首席執行官亞歷克斯·茲懷爾將出席第35屆Roth年會。該公司專注於為罕見和複雜的中樞神經系統疾病患者發現和開發創新療法。
Event |
35th Annual Roth Conference |
Date |
March 13, 2023 |
Presentation |
10:00 AM Pacific Time (1:00 PM Eastern Time) |
Location |
Dana Point, CA |
事件 |
第35屆Roth年會 |
日期 |
2023年3月13日 |
介紹 |
太平洋時間上午10：00(東部時間下午1：00) |
位置 |
加利福尼亞州達納角 |
This year's event will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, thematic industry panels, and company presentations by executive management from approximately 400 private and public companies in a variety of growth sectors including: Business Services, Consumer / Health & Wellness, Healthcare, Resources: Oil & Gas / Metals & Mining, Technology, Media & AgTech and Sustainability/ESG.
今年的活動將包括一對一/小組會議、分析師選擇的爐邊聊天、主題行業小組討論以及來自各種成長型行業的約400傢俬營和上市公司的高管管理層的公司演示，這些公司包括：商業服務、消費者/健康和健康、醫療保健、資源：石油和天然氣/金屬和採礦、技術、媒體和農業技術以及可持續/ESG。
To learn more and submit a registration request, visit
要了解更多資訊並提交註冊申請，請訪問
The live audio webcast and replay will be available in the investor relations section of the Company's website at
現場音頻網路直播和重播將在公司網站的投資者關系部分播出，網址為：
About ROTH MKM
關於Roth MKM
ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information, please visit .
Roth MKM是一家關係驅動型投資銀行，專注於為成長型公司及其投資者提供服務。我們的全方位服務平臺提供融資、高影響力的股票研究、宏觀經濟學、銷售和交易、技術洞察、衍生品策略、並購諮詢和企業準入。Roth MKM總部設在加利福尼亞州紐波特海灘，是一傢俬人所有的員工所有的組織，在美國各地設有辦事處。
About NLS Pharmaceutics Ltd.
關於NLS製藥有限公司
NLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS製藥有限公司(納斯達克代碼：NLSP)是一家全球開發期生物製藥公司，與世界級合作夥伴和國際公認的科學家網絡合作，專注於為患有罕見和複雜的中樞神經系統疾病的患者發現和開發創新療法，這些患者的醫療需求尚未得到滿足。NLS總部設在瑞士，成立於2015年，由一支經驗豐富的管理團隊領導，該團隊在開發和商業化候選產品方面有著良好的記錄。欲瞭解更多資訊，請訪問。
For additional information:
有關更多資訊，請訪問：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
Marianne Lambertson(投資者和媒體)
NLS製藥有限公司。
+1 239.682.8500
郵箱：ml@nls-pharma.com
SOURCE: NLS Pharmaceutics Ltd.
資料來源：NLS製藥有限公司。